Patent · US Active

Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof

US10821166B2 · kind B2 · utility

3Cited by

16References

18Claims

0Family size

Assignees

Valneva Austria GmbH · AT
Valneva USA, Inc. · US

Inventors

Larry R. Ellingsworth · San Jose, US
David Flyer · Olney, US
Jing-Hui Tian · Germantown, US
Steven R. Fuhrmann · Germantown, US
Stefanie Kluepfel-Stahl · Bethesda, US
Gregory M. Glenn · Bethesda, US
Kerstin Westritschnig · Wien, AT

Key dates

Filing date	Mar 7, 2019
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Mar 7, 2039

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.